NASDAQ · ENTA
Enanta Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ENTA: Nov 16, 2026
Enanta Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/16/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.82. The reported EPS for the same quarter last year was $-0.87.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.82 | $-0.70 | $-0.95 | 2 |
| Dec 2026 | $-0.58 | $-0.58 | $-0.58 | 1 |
| Mar 2027 | $-0.59 | $-0.59 | $-0.59 | 1 |
| Jun 2027 | $-0.57 | $-0.57 | $-0.57 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews- Fintel · Oct 29, 11:11 PM EDTUnified Patent Court Rules Enanta Pharmaceuticals, Inc. Patent EP 4 051 265 InvalidEnanta Pharmaceuticals, Inc. announced that on October 29, 2026, the Unified Patent Court of the European Union released its decision concluding that European Patent No. EP 4 051 265 is invalid. The court also determined that the patent infringement action was unfounded in light
- Fintel · Oct 28, 12:23 PM EDTEnanta Pharmaceuticals, Inc. Announces Planned Retirement of CEO Jay R. Luly, Ph.D. by February 1, 2027On October 28, 2026, Enanta Pharmaceuticals, Inc. announced that Jay R. Luly, Ph.D., age 70, intends to retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership with the Company. The Company expects to enter into an agreement with Dr.
- Zacks · Aug 10, 5:10 PM EDTEnanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue EstimatesEnanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 5, 6:10 PM EDTCoherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue EstimatesCoherus Oncology (CHRS) delivered earnings and revenue surprises of -337.50% and -45.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 21, 10:08 AM EDTNuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- Zacks · Jun 24, 9:13 AM EDTEnanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- RTTNews · May 19, 6:32 AM EDTEnanta Pharma's RSV Bet And Immunology Ambitions(RTTNews) – Enanta Pharmaceuticals Inc. (ENTA), a clinical-stage biotechnology company focusing on viral infections and immunological diseases, will be highlighting its investigational programs – Zelicapavir and EPS-3903 – at the American Thoracic Society (ATS) International Conf
- Zacks · May 11, 5:10 PM EDTEnanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue EstimatesEnanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.17% and -2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 5:55 PM EDTArcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue EstimatesArcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +16.91% and -73.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 9:02 AM EDTEnanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Zacks · Feb 12, 12:00 PM ESTWhat Makes Enanta Pharmaceuticals (ENTA) a New Buy StockEnanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Feb 9, 5:05 PM ESTEnanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue EstimatesEnanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +21.50% and +19.52%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Enanta Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.